Trial · NCT02289950
Results by group30
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 30
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression Free Survival (PFS) | Farletuzumab 5 mg/kg + Carboplatin/Paclitaxel or Carboplatin/PLD | 11.73 | 95% Confidence Interval 10.22 to 13.60 | Months | |
| Progression Free Survival (PFS) | Placebo + Carboplatin/Paclitaxel or Carboplatin/PLD | 10.78 | 95% Confidence Interval 9.49 to 13.17 | Months | |
| Overall Survival (OS) | Farletuzumab 5 mg/kg + Carboplatin/Paclitaxel or Carboplatin/PLD | 43.07 | 95% Confidence Interval 37.13 to NA | Months | |
| Overall Survival (OS) | Placebo + Carboplatin/Paclitaxel or Carboplatin/PLD | 42.45 | 95% Confidence Interval 37.85 to NA | Months | |
| Number of Participants With Best Overall Response (BOR) | Farletuzumab 5 mg/kg + Carboplatin/Paclitaxel or Carboplatin/PLD | Complete Response | 24 | Participants | |
| Number of Participants With Best Overall Response (BOR) | Placebo + Carboplatin/Paclitaxel or Carboplatin/PLD | Complete Response | 15 | Participants | |
| Number of Participants With Best Overall Response (BOR) | Farletuzumab 5 mg/kg + Carboplatin/Paclitaxel or Carboplatin/PLD | Partial Response | 72 | Participants | |
| Number of Participants With Best Overall Response (BOR) | Placebo + Carboplatin/Paclitaxel or Carboplatin/PLD | Partial Response | 35 | Participants | |
| Number of Participants With Best Overall Response (BOR) | Farletuzumab 5 mg/kg + Carboplatin/Paclitaxel or Carboplatin/PLD | Stable Disease | 36 | Participants | |
| Number of Participants With Best Overall Response (BOR) | Placebo + Carboplatin/Paclitaxel or Carboplatin/PLD | Stable Disease | 17 | Participants | |
| Time to Tumor Response (TTR) | Farletuzumab 5 mg/kg + Carboplatin/Paclitaxel or Carboplatin/PLD | 2.69 | 95% Confidence Interval 1.74 to 2.83 | months | |
| Time to Tumor Response (TTR) | Placebo + Carboplatin/Paclitaxel or Carboplatin/PLD | 2.53 | 95% Confidence Interval 1.48 to 2.69 | months | |
| Duration of Response (DOR) | Farletuzumab 5 mg/kg + Carboplatin/Paclitaxel or Carboplatin/PLD | 10.12 | 95% Confidence Interval 8.54 to 11.47 | months | |
| Duration of Response (DOR) | Placebo + Carboplatin/Paclitaxel or Carboplatin/PLD | 8.51 | 95% Confidence Interval 6.31 to 10.97 | months | |
| Percentage of Participants Achieving Each Second Platinum-Free Interval Stratified by First Platinum-Free Interval | Farletuzumab 5 mg/kg + Carboplatin/Paclitaxel or Carboplatin/PLD | Second platinum free interval (<6 months): First platinum free interval (6 to 12 months) | 71.2 | 95% Confidence Interval 57.92 to 82.24 | percentage of participants |
| Percentage of Participants Achieving Each Second Platinum-Free Interval Stratified by First Platinum-Free Interval | Placebo + Carboplatin/Paclitaxel or Carboplatin/PLD | Second platinum free interval (<6 months): First platinum free interval (6 to 12 months) | 63.3 | 95% Confidence Interval 43.86 to 80.07 | percentage of participants |
| Percentage of Participants Achieving Each Second Platinum-Free Interval Stratified by First Platinum-Free Interval | Farletuzumab 5 mg/kg + Carboplatin/Paclitaxel or Carboplatin/PLD | Second platinum free interval (6-12 months): First platinum free interval (6 to 12 months) | 6.8 | 95% Confidence Interval 1.88 to 16.46 | percentage of participants |
| Percentage of Participants Achieving Each Second Platinum-Free Interval Stratified by First Platinum-Free Interval | Placebo + Carboplatin/Paclitaxel or Carboplatin/PLD | Second platinum free interval (6-12 months): First platinum free interval (6 to 12 months) | 23.3 | 95% Confidence Interval 9.93 to 42.28 | percentage of participants |
| Percentage of Participants Achieving Each Second Platinum-Free Interval Stratified by First Platinum-Free Interval | Farletuzumab 5 mg/kg + Carboplatin/Paclitaxel or Carboplatin/PLD | Second platinum free interval (>12-36 months): First platinum free interval (6 to 12 months) | 16.9 | 95% Confidence Interval 8.44 to 28.97 | percentage of participants |
| Percentage of Participants Achieving Each Second Platinum-Free Interval Stratified by First Platinum-Free Interval | Placebo + Carboplatin/Paclitaxel or Carboplatin/PLD | Second platinum free interval (>12-36 months): First platinum free interval (6 to 12 months) | 10.0 | 95% Confidence Interval 2.11 to 26.53 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02289950/results